Optimi Health (TSE:OPTI) has released an update.
Optimi Health Corp., a leader in psychedelics pharmaceutical manufacturing, has successfully completed a $1.5 million financing round through three tranches, with the funds slated to support the company’s efforts to obtain a Drug Establishment License, propel commercialization, and provide general working capital. Investors in the non-brokered private placement received units priced at CAD$0.30, comprising one common share and a half warrant, which allows the purchase of additional shares at CAD$0.40 within two years, subject to certain conditions. The recently raised capital underscores Optimi’s ongoing commitment to being a premier supplier of controlled substances like psilocybin and MDMA.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
